金吾财讯 | Vertex Pharmaceuticals (VRTX) 与 Crinetics Pharmaceuticals (CRNX) 共同披露收购协议，企业将以每股 85 美元现金完成标的全额收购，交易对应 Crinetics 整体股权价值约 100 亿美元，扣除标的账面现金后净交易对价 88 亿美元，交易预计 2026 年第三季度完成，消息落地后 Crinetics 盘后股价实现翻倍上涨。
本次收购核心看点为 Crinetics 成熟商业化管线与在研创新药，已获批药物 Palsonify 用于成人肢端肥大症治疗，落地后将直接为 Vertex 带来持续性营收增量；在研管线 Atumelnan 针对先天性肾上腺皮质增生症，市场空间达数十亿美元，同时可拓展库欣综合征治疗适应症，机构测算管线峰值年营收有望突破 50 亿美元，支撑企业长期双位数收入增速与行业领先运营利润率。
Vertex 计划依托自有现金搭配债务工具完成交易资金筹措，美国银行、摩根士丹利提供 45 亿美元全额过渡性融资，收购落地后企业罕见病内分泌赛道产品矩阵将实现大幅扩容。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.